Who we are
cliexa stands for CLInical EXcellence and Algorithms. Our name embodies our commitment to transforming healthcare through advanced technology. By integrating clinical insights, excellence in patient care, and cutting-edge algorithms, we provide a robust AI-powered platform that engages, integrates, and delivers actionable insights to clinical teams and their partners.
Why "cliexa" is Lowercase
The emphasis on “Excellence” is a core aspect of our brand identity. The decision to use a lowercase “c” in “cliexa” is deliberate and meaningful. It underscores our commitment to excellence in clinical outcomes while maintaining a modern and approachable brand image.
The lowercase “c” reflects our innovative and forward-thinking approach, aligning with our mission to set new standards in clinical excellence. It visually represents the idea that while we may be humble in our approach, our ambition and focus on excellence drive everything we do.
By prioritizing “Excellence,” we highlight the most important aspect of our work: delivering outstanding clinical solutions through advanced algorithms. This branding choice helps reinforce our dedication to achieving and exceeding the highest standards in healthcare.
Our Values
Primary Value
Our Team
Mehmet Kazgan MSc, MBA
Founder, CEO
Haluk Yilmazturk, MBA
Co-Founder, Chief Administrative Officer
Srini Bollimpali, MD, MSA
Chief Medical Officer
Arin Seidlitz
Director of Product
Christa Kubbery PhD
Chief Devolopment Officer
Turk Kilavuz, MD
Strategic Business Development Executive
Christian Hageseth
Chief Investment Officer
Burak Cetin
Director of Architecture
Our Story
Since our inception in 2016, cliexa has been dedicated to revolutionizing healthcare by harnessing the power of patient-reported data. Founded with a vision to break down barriers within the healthcare system, our team of medical professionals and computer engineers has worked tirelessly to simplify healthcare for both patients and providers.
The journey began with a focus on enhancing diagnostic insights through cliexaDiagnostics and tracking treatment progress with cliexaTrac, initially designed for Arthritis and Pain management. Our advanced interoperability platform, cliexaConnect, was introduced to efficiently aggregate and process patient data, integrating patented cliexaProtocols directly into patient charts to streamline clinical workflows and improve care coordination from 2016 to 2018.
Building on this foundation, our partnership and investment from the American College of Cardiology from 2018 to 2021 propelled us forward. This collaboration expanded cliexaTrac to integrate mobile technology with over 300 medical devices, enabling remote patient monitoring and validating device data with proprietary monitoring algorithms.
Recently, our partnership and investment from Mayo Clinic Platform from 2022 to 2024 has led to the introduction of cliexaProspect, a cutting-edge AI-powered Risk Prediction Platform. Validated with real patient data, cliexaProspect enhances predictive analytics capabilities, supporting proactive healthcare interventions and marking another milestone in our journey towards transforming healthcare delivery.
